Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1%
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Green Cross Corp
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Deferred Income Tax
â‚©2.3B
CAGR 3-Years
-18%
CAGR 5-Years
6%
CAGR 10-Years
-12%
Celltrion Inc
KRX:068270
Deferred Income Tax
â‚©119.5B
CAGR 3-Years
42%
CAGR 5-Years
15%
CAGR 10-Years
48%
SK Bioscience Co Ltd
KRX:302440
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Deferred Income Tax
â‚©1.5B
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Deferred Income Tax
â‚©2.3B
CAGR 3-Years
-20%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Deferred Income Tax
â‚©6.4m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Deferred Income Tax?
Deferred Income Tax
2.3B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Deferred Income Tax amounts to 2.3B KRW.

What is Green Cross Corp's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
-12%

Over the last year, the Deferred Income Tax growth was 53%. The average annual Deferred Income Tax growth rates for Green Cross Corp have been -18% over the past three years , 6% over the past five years , and -12% over the past ten years .

Back to Top